Clinical Topics   /   Therapy

Cyramza Receives Fast-Track Approval for Advanced Stomach Cancer

By US Medicine

INDIANAPOLIS – A new therapy has received fast-track approval for treatment of advanced stomach cancer. The Food and Drug Administration has approved Cyramza (ramucirumab) to treat patients with gastroesophageal junction adenocarcinoma. Cyramza, marketed by Eli Lilly of Indianapolis, is an angiogenesis inhibitor that blocks the blood supply to tumors. It is intended for patients with unresectable cancer or metastatic cancer after being treated with a fluoropyrimidine- or platinum-containing therapy. “Although the rates of stomach cancer in the United States have decreased over the past 40 years, patients require new treatment options, particularly when they no longer respond to other therapies,” said Richard Pazdur, MD, director of the Office of Hematology and Oncology Products in the FDA’s Center for Drug Evaluation and Research. “Cyramza is new treatment option that has demonstrated an ability to extend patients’ lives and slow tumor growth.” Cyramza’s safety and effectiveness were evaluated in a clinical trial of 355 participants with unresectable or metastatic stomach or gastroesophageal junction cancer. Results indicated that participants treated with Cyramza had a median overall survival of 5.2 months compared to 3.8 months in participants receiving placebo. Additionally, participants who took Cyramza experienced a delay in tumor growth compared to participants who were given placebo. Results from a second clinical trial that evaluated the efficacy of Cyramza plus paclitaxel vs. paclitaxel alone also showed an improvement in overall survival. Diarrhea and high blood pressure were common side effects experienced by Cyramza-treated participants during clinical testing. The FDA reviewed Cyramza under its priority review program, which provides an expedited review for drugs that have the potential, at the time the application was submitted, to be a significant improvement in safety or effectiveness in the treatment of a serious condition. Cyramza was also granted orphan product designation because it is intended to treat a rare disease or condition.

Related Articles

VA Patients Lack Testing to Optimize CLL Treatment

SALT LAKE CITY — The presence of deletion 17p (del17), determined by chromosome analysis and/or fluorescence in situ hybridization (FISH), is a strong negative prognostic marker in chronic lymphocytic leukemia (CLL), according to a report in the Journal of Clinical Oncology.1

Lobectomy Still Has Significant Survival Benefit in Early NSCLC

While increased use of stereotactic body radiation might have played a key role in doubling survival rates for early-stage non-small cell lung cancer (NSCLC) among veterans between 2001 and 2010 compared to conventional radiation, a new study confirms that isn’t always the best way to assure longer survival.


U.S. Medicine Recommends


More From oncology

Oncology

VA Patients Lack Testing to Optimize CLL Treatment

SALT LAKE CITY — The presence of deletion 17p (del17), determined by chromosome analysis and/or fluorescence in situ hybridization (FISH), is a strong negative prognostic marker in chronic lymphocytic leukemia (CLL), according to a report in the Journal of Clinical Oncology.1

Oncology

Lobectomy Still Has Significant Survival Benefit in Early NSCLC

While increased use of stereotactic body radiation might have played a key role in doubling survival rates for early-stage non-small cell lung cancer (NSCLC) among veterans between 2001 and 2010 compared to conventional radiation, a new study confirms that isn’t always the best way to assure longer survival.

Oncology

Gene Assay Can Help Determine Active Surveillance Usefulness

Vascular Events Lead to Stroke About a Fourth of the Time. INDIANAPOLIS — While many healthcare systems measure the quality of their stroke care, looking at performance early in the vascular disease process can help... View Article

Breast Cancer

Chemotherapy Use Declines for Breast Cancer Patients

With growing concern about overtreatment of breast cancer as outcomes have improved over time, not much research has been performed on how chemotherapy use and oncologists' recommendations have changed in recent years.

Oncology

Laparoscopic, Robotic Surgeries Equivalent for Pancreatic Cancer

Pancreatic cancer patients increasingly are receiving minimally invasive pancreaticoduodenectomy (MIPD).

Facebook Comment

Subscribe to U.S. Medicine Print Magazine

U.S. Medicine is mailed free each month to physicians, pharmacists, nurse practitioners, physician assistants and administrators working for Veterans Affairs, Department of Defense and U.S. Public Health Service.

Subscribe Now

Receive Our Email Newsletter

Stay informed about federal medical news, clinical updates and reports on government topics for the federal healthcare professional.

Sign Up